CTI BioPharma Corp.
CTI BioPharma Corp. (CTIC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ctic · stock forecast · 19 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Buy
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$13.00
Consensus
$10.40
+14.4% upside
Low
$9.00
Median: $9 · Last Close: $9.09
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$10.40
14.4% upside
High Target
$13
43.0%
Low Target
$9
-1.0%
Current Price
$9.09
as of today
Based on analyst price targets, the CTIC stock price prediction for the next 12 months ranges from $9 to $13. The consensus CTIC price forecast of $10.40 implies 14.4% upside from the current price of $9.09.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $9.09 | ↓ 0.03% |
1-day model range: $9.08–$9.09. Peak: $9.09 (-0.03%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CTIC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-24 | JMP Securities | Maintains | Market Perform→Perform |
| 2023-05-16 | SVB Leerink | Downgrade ↓ | Outperform→Perform |
| 2023-05-15 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-05-11 | Needham | Downgrade ↓ | Buy→Hold |
| 2023-05-11 | JMP Securities | Downgrade ↓ | Market Outperform→Perform |
| 2023-04-19 | Needham | Maintains | Buy→Buy |
| 2023-04-17 | TD Cowen | Maintains | Outperform→Outperform |
| 2023-03-07 | JMP Securities | Maintains | Market Outperform→Outperform |
| 2023-03-06 | Needham | Maintains | Buy→Buy |
| 2023-02-06 | JMP Securities | Maintains | Market Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on CTI BioPharma Corp. (CTIC) stock. Of the recent 40 rating actions, 1 were upgrades and 8 were downgrades. 19 analysts currently cover CTIC.
Analyst Recommendation Trends
CTIC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast CTIC EPS of $— for the current fiscal year, based on estimates from 0 analysts. The CTIC revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CTIC stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CTIC price target is $10.40 (+14.4% upside), with an analyst consensus of Buy.
The CTIC short-term stock prediction for tomorrow is $9.09 (-0.03%).
CTI BioPharma Corp. trades on NASDAQ under the ticker CTIC. The CTIC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 68% of covering analysts.
Frequently asked questions
CTIC forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month CTIC price target is $10.40, with a high forecast of $13.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies +14.4% potential upside from the current price of $9.09.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.